<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0004308'>Ventricular arrhythmias</z:hpo> remain a lethal complication of <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes (ACS) </plain></SENT>
<SENT sid="1" pm="."><plain>However, the incidence and prognosis of sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo>/<z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We examined the incidence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> and subsequent survival among 9211 patients enrolled in the Early <z:chebi fb="2" ids="17089">Glycoprotein</z:chebi> IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial </plain></SENT>
<SENT sid="3" pm="."><plain>The cumulative incidence of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was 1.5% (n=141); 0.6% (n=55) had VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> ≤48 hours after enrollment, and 0.9% (n=86) had VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> &gt;48 hours after enrollment </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> more frequently had prior <z:hpo ids='HP_0001635'>heart failure</z:hpo>, an ejection fraction &lt;30%, and triple-vessel <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Predictors of sustained VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> were similar regardless of the timing of VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (≤48 versus &gt;48 hours) </plain></SENT>
<SENT sid="6" pm="."><plain>Patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> ≤48 hours after enrollment had higher 30-day mortality than those who did not have VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> ���48 hours (13.0% versus 2.2%; adjusted odds ratio, 6.73; 95% confidence interval, 2.68-16.9) </plain></SENT>
<SENT sid="7" pm="."><plain>The increased risk of <z:hpo ids='HP_0011420'>death</z:hpo> associated with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> ≤48 hours persisted at 1 year </plain></SENT>
<SENT sid="8" pm="."><plain>The risk of mortality, relative to patients without VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>, was greater for patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> &gt;48 hours (hazard ratio, 20.70; 95% confidence interval, 15.39-27.85) than for those with earlier VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (hazard ratio, 7.45; 95% confidence interval, 4.60-12.08; P=0.0003) </plain></SENT>
<SENT sid="9" pm="."><plain>The frequency of arrhythmic <z:hpo ids='HP_0011420'>death</z:hpo> was higher in patients with VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> than in those without VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> (26.4% versus 6.9%) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Sustained VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> is infrequent after NSTE ACS but is as likely to occur after 48 hours as within the first 48 hours </plain></SENT>
<SENT sid="11" pm="."><plain>The marked increase in <z:hpo ids='HP_0000001'>all</z:hpo>-cause <z:hpo ids='HP_0011420'>death</z:hpo> among NSTE ACS patients with both early and late sustained VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> raises important considerations for aggressive monitoring beyond 48 hours and interventions to prevent arrhythmic <z:hpo ids='HP_0011420'>death</z:hpo> in these patients </plain></SENT>
<SENT sid="12" pm="."><plain>CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="13" pm="."><plain>Unique identifier: NCT00089895 </plain></SENT>
</text></document>